Last Updated: November 16, 2026

Investigational Drug Information for Itacitinib

« Back to Dashboard


What is the development status for investigational drug Itacitinib?

Itacitinib is an investigational drug.

There have been 53 clinical trials for Itacitinib. The most recent clinical trial was a Phase 3 trial, which was initiated on July 19th 2017.

The most common disease conditions in clinical trials are Graft vs Host Disease, Primary Myelofibrosis, and Neoplasms. The leading clinical trial sponsors are Incyte Corporation, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are four hundred and seventy-one US patents protecting this investigational drug and zero international patents.

Recent Clinical Trials for Itacitinib
TitleSponsorPhase
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsIncyte CorporationPhase 1
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyIncyte CorporationPhase 2

See all Itacitinib clinical trials

Clinical Trial Summary for Itacitinib

Top disease conditions for Itacitinib
Top clinical trial sponsors for Itacitinib

See all Itacitinib clinical trials

US Patents for Itacitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Itacitinib ⤷  Start Trial Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Start Trial
Itacitinib ⤷  Start Trial Preparation method for aromatic heterocyclic compound used as selective JAK3 and/or JAK1 kinase inhibitor and application of aromatic heterocyclic compound Chipscreen Biosciences Ltd ⤷  Start Trial
Itacitinib ⤷  Start Trial Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
Itacitinib ⤷  Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Start Trial
Itacitinib ⤷  Start Trial Tank-binding kinase inhibitor compounds Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
Itacitinib ⤷  Start Trial Methods of treating pediatric cancers Loxo Oncology, Inc. (Stamford, CT) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Itacitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Itacitinib World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Start Trial
Itacitinib Argentina AR096246 2033-05-09 ⤷  Start Trial
Itacitinib Australia AU2014262622 2033-05-09 ⤷  Start Trial
Itacitinib Brazil BR112015028017 2033-05-09 ⤷  Start Trial
Itacitinib Canada CA2911408 2033-05-09 ⤷  Start Trial
Itacitinib Chile CL2015003280 2033-05-09 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Itacitinib Development Update, Patent Position, and Market Projection

Last updated: September 7, 2026

Itacitinib, Incyte’s selective JAK1 inhibitor, has no FDA approval and no commercial revenue. Its leading development program in steroid-refractory acute graft-versus-host disease failed the Phase 3 GRAVITAS-301 trial, and Incyte discontinued further development in that indication. The near-term commercial outlook is therefore effectively zero unless a new sponsor revives the asset for another indication.

What is the current development status of itacitinib?

Itacitinib, also known as INCB039110, is an oral, selective Janus kinase 1 inhibitor designed to reduce signaling through cytokines including interferon-gamma, interleukin-6 and other inflammatory pathways.

Incyte advanced itacitinib primarily for graft-versus-host disease, or GVHD, following encouraging earlier-stage data. The key program was:

Item Status
Active ingredient Itacitinib, INCB039110
Developer Incyte Corp.
Mechanism Selective JAK1 inhibition
Lead indication Steroid-refractory acute GVHD
Pivotal study GRAVITAS-301, Phase 3
Comparator Placebo plus corticosteroids
Primary endpoint Day-28 overall response rate
Result Primary endpoint not met
FDA approval None
Commercial sales None
Current outlook Development discontinued in the lead indication

Incyte reported that GRAVITAS-301 did not meet its primary endpoint. The overall response rate at Day 28 was not statistically superior to placebo plus corticosteroids. The result removed the principal regulatory path for itacitinib in acute GVHD and materially reduced the value of the broader program.[1]

Why did the GRAVITAS-301 trial fail?

The GRAVITAS-301 trial tested itacitinib in patients with steroid-refractory acute GVHD. Patients received itacitinib or placebo in combination with corticosteroids.

The trial did not demonstrate a statistically significant improvement in the Day-28 overall response rate. The result was commercially important because acute GVHD was the most advanced indication and had a defined pathway to regulatory review.

The failure also weakened the case for using a selective JAK1 inhibitor as a broad replacement or complement to approved GVHD therapies. JAK pathway modulation remains biologically relevant in GVHD, but clinical benefit depends on disease setting, treatment line, corticosteroid exposure and the degree of inflammatory pathway suppression.

What were the key clinical risks?

The main development risks were:

  1. The lead endpoint was an early response endpoint rather than a durable survival endpoint.
  2. GVHD is biologically heterogeneous and difficult to treat with a single pathway inhibitor.
  3. Existing and emerging therapies created a higher efficacy benchmark.
  4. Itacitinib had to demonstrate benefit on top of corticosteroids in a heavily pretreated population.
  5. A failed Phase 3 study sharply reduced the probability of regulatory recovery without a new indication or confirmatory trial.

What indications were studied for itacitinib?

Itacitinib was evaluated across inflammatory, hematologic and immune-mediated conditions. The most commercially relevant program was acute GVHD.

Indication or setting Development status Commercial assessment
Steroid-refractory acute GVHD Phase 3 failed Lead program discontinued
Chronic GVHD-related studies Earlier-stage investigation No established regulatory path
Myelofibrosis and other myeloproliferative disorders Combination and exploratory studies Superseded by more advanced JAK programs
Solid tumors and inflammatory diseases Early clinical research No validated commercial indication
Cytokine-driven disorders Exploratory No public approval pathway

Earlier studies suggested that itacitinib could be administered with corticosteroids and might reduce inflammatory activity without producing the full degree of myelosuppression associated with broader JAK inhibition. Those findings were insufficient to overcome the negative Phase 3 result.

When does itacitinib lose exclusivity?

Itacitinib has no FDA-approved product and therefore has no approved-drug exclusivity period, Orange Book listing or commercial launch date.

Patent exclusivity is separate from FDA regulatory exclusivity. Incyte may have held or pursued composition-of-matter, formulation, method-of-use and manufacturing patents covering itacitinib. However, the practical value of those rights is limited by the absence of an approved product and by the lack of a current commercial development program.

Exclusivity category Itacitinib status
New chemical entity exclusivity Not triggered because there is no approval
Orphan-drug exclusivity No approved orphan indication identified
Pediatric exclusivity None
Patent term extension None available without an approved product
Orange Book patent listing None
Paragraph IV litigation No public commercial challenge identified
Biosimilar exclusivity Not applicable

An original composition patent could still block development by third parties until expiration, depending on claim scope and enforceability. That would not create revenue for Incyte unless the company or a licensee resumed development.

What patents protect itacitinib?

The relevant patent categories are likely to include:

  • Composition-of-matter claims covering the itacitinib molecule and related compounds.
  • Pharmaceutical-composition claims covering tablets, salts, dosage forms or excipients.
  • Method-of-treatment claims covering JAK1-mediated diseases.
  • Combination claims covering itacitinib with corticosteroids or other immunomodulators.
  • Manufacturing claims covering intermediates, synthetic routes or polymorphic forms.

The patent position cannot be equated with an approved-product patent estate. No Orange Book listing establishes which patents would have been asserted against an abbreviated new drug application. No public commercial Paragraph IV dispute has created a tested litigation record for itacitinib.

How strong is the itacitinib patent estate?

The estate is strategically weaker than the patent estate of an approved, revenue-generating drug for four reasons:

  1. It lacks Orange Book linkage.
  2. It has no marketed formulation requiring protection.
  3. It has no validated method-of-use patent around a commercially accepted label.
  4. Any third-party investment would require both freedom to operate and a new clinical-development thesis.

Composition-of-matter protection would be the strongest category. Method-of-use claims would be more vulnerable to design-around strategies, alternative dosing regimens and indication-specific validity challenges.

What is the FDA regulatory status of itacitinib?

Itacitinib is not FDA approved. The GRAVITAS-301 failure prevented the filing of a conventional marketing application for the lead GVHD indication based on that program.

There is:

  • No approved label.
  • No FDA-approved dosage.
  • No marketed formulation.
  • No Orange Book entry.
  • No FDA reference-listed drug.
  • No approved indication.
  • No regulatory exclusivity.
  • No established generic approval pathway.

Because itacitinib has no reference-listed drug, generic manufacturers cannot use the standard ANDA pathway against an approved itacitinib product. A future developer would likely need to pursue a full 505(b)(1) or 505(b)(2) strategy, depending on the formulation, indication and available clinical data.

What is the competitive landscape for itacitinib?

Itacitinib competes against approved therapies and pipeline assets that target GVHD through different mechanisms.

Product Active ingredient Company Relevant position
Jakafi Ruxolitinib Incyte FDA-approved for steroid-refractory acute and chronic GVHD
Rezurock Belumosudil Sanofi FDA-approved for chronic GVHD after multiple prior lines
Ojjaara Momelotinib GSK Approved for myelofibrosis, not GVHD
Axatilimab Axatilimab Syndax Pharmaceuticals Approved in chronic GVHD after prior systemic therapies
Steroids Prednisone and related agents Multiple Standard initial therapy
Extracorporeal photopheresis Procedure Multiple providers Used in selected refractory disease
Clinical-stage cellular and antibody therapies Various Multiple Compete for later-line GVHD treatment

Incyte’s own Jakafi creates the most direct internal competitive issue. Jakafi has regulatory approval and commercial infrastructure in GVHD, while itacitinib lacks clinical validation in the lead setting. That reduces the incentive to replace or cannibalize an established product unless itacitinib offers a clear efficacy, tolerability or combination advantage.[2]

How does itacitinib compare with ruxolitinib?

Ruxolitinib inhibits JAK1 and JAK2 and has an established clinical and regulatory position. Itacitinib was designed to be more selective for JAK1.

Attribute Itacitinib Ruxolitinib
JAK activity Selective JAK1 JAK1/JAK2
FDA approval None Multiple indications, including GVHD
GVHD evidence Phase 3 failure in acute GVHD Positive regulatory evidence
Commercial status No revenue Established commercial product
Myelosuppression concern Intended to reduce broader JAK-related effects Known risk, especially in vulnerable patients
Patent and regulatory value Unvalidated Mature, approved-product estate
Generic risk No ANDA pathway currently Generic entry depends on indication and listed patents

Itacitinib’s selectivity was a potential differentiation point, not a demonstrated commercial advantage. A selective mechanism must translate into measurable benefits such as lower infection risk, lower cytopenia rates, improved steroid tapering or better survival. The pivotal data did not establish that profile.

What market could itacitinib address?

The theoretical market opportunity was concentrated in refractory GVHD, a serious complication of allogeneic hematopoietic stem-cell transplantation.

The addressable patient population is limited by:

  • The number of annual allogeneic transplants.
  • The incidence of acute and chronic GVHD.
  • The share requiring systemic therapy.
  • The percentage becoming steroid-refractory.
  • Treatment duration and line of therapy.
  • Payer restrictions and hospital formulary decisions.

A commercial launch could have supported a specialty-drug price in the approximate range used for other targeted hematology therapies, but the public record does not establish an approved price, treatment duration or payer-assigned net price for itacitinib. Any revenue projection based on a precise price would therefore be speculative.

What is the realistic market projection?

Scenario Probability assessment Revenue outlook
No restart of development Most likely based on the failed Phase 3 program Zero commercial revenue
Licensing to a specialty hematology company Possible but difficult Limited value until a new clinical thesis is validated
New GVHD trial Low near-term probability Requires substantial additional clinical investment
New non-GVHD indication Low probability Could create value only after proof-of-concept
Commercial launch before 2028 No credible basis identified Not supportable from public development status

The base-case forecast is zero near-term revenue. The asset has option value, but not a defensible launch forecast. A new sponsor would need to fund formulation work, regulatory interactions and clinical trials while competing against approved therapies.

Which companies could challenge or license itacitinib?

No public generic company has an established commercial challenge against itacitinib because there is no approved reference product.

Potential counterparties would be specialty hematology companies, transplant-focused pharmaceutical companies and firms seeking immunology assets. The most logical transaction would be an option-based licensing structure with milestone payments tied to:

  • New indication selection.
  • Regulatory alignment.
  • Phase 2 response data.
  • A registrational trial decision.
  • Commercial approval.

A conventional high-upfront licensing deal would be difficult to justify after the failed GRAVITAS-301 study unless the asset had compelling new biomarker data or a clearly differentiated safety profile.

What patent litigation and settlement risks exist?

No major public patent litigation or Paragraph IV settlement has established an itacitinib market-entry timetable.

The principal legal risks for a future developer would be:

  • Infringement claims based on composition patents.
  • Method-of-use claims covering JAK1 inhibition in GVHD.
  • Formulation claims covering a commercially practical oral dosage form.
  • Patent-term limitations caused by the age of the original filings.
  • Invalidity challenges based on obviousness or lack of written description.
  • Ownership disputes involving development rights or regional licenses.

A third party could also pursue a non-infringement position by using a different salt, formulation, dosing schedule or treatment indication. The strength of that strategy would depend on the live claims at the time of development.

What manufacturing and intellectual-property barriers affect itacitinib?

The manufacturing barrier is likely moderate rather than prohibitive for a small-molecule JAK inhibitor. A commercial program would require:

  • A reproducible synthetic route.
  • Control of impurities and genotoxic intermediates.
  • Solid-state and polymorph characterization.
  • Stable oral tablets or capsules.
  • Scale-up validation.
  • Good Manufacturing Practice production.
  • Long-term stability data.
  • A supply chain for active pharmaceutical ingredient.

The primary barrier is clinical and regulatory, not chemical manufacturing. A company could probably develop a manufacturing process, but it would still face patent clearance, clinical-trial costs and competition from approved GVHD products.

What would trigger a positive revaluation of itacitinib?

The asset would require evidence that addresses the GRAVITAS-301 failure. The most important catalysts would be:

  1. A new indication with a stronger biological rationale.
  2. Biomarker-defined patient selection.
  3. Demonstrated steroid-sparing activity.
  4. Lower rates of cytopenia or infection than broader JAK inhibitors.
  5. Positive combination data with an approved GVHD therapy.
  6. A credible FDA development pathway.
  7. A license or acquisition by a company with transplant-market infrastructure.

Absent those events, itacitinib should be valued as a discontinued clinical asset rather than as a late-stage product candidate.

Key Takeaways

  • Itacitinib is an investigational selective JAK1 inhibitor developed by Incyte.
  • Its pivotal GRAVITAS-301 trial in steroid-refractory acute GVHD failed its primary endpoint.
  • Incyte discontinued development in the lead GVHD program.
  • Itacitinib has no FDA approval, Orange Book listing, regulatory exclusivity or commercial revenue.
  • No established Paragraph IV challenge, generic launch date or settlement timetable exists.
  • Ruxolitinib, belumosudil and newer GVHD therapies have stronger regulatory and commercial positions.
  • The near-term market projection is zero revenue.
  • Any future value depends on a new indication, biomarker strategy, licensing transaction or successful clinical repositioning.

Frequently Asked Questions

Is itacitinib approved by the FDA?

No. Itacitinib has not received FDA approval for GVHD, myelofibrosis, cancer or any other indication.

Did Incyte discontinue itacitinib?

Incyte discontinued development after the Phase 3 GRAVITAS-301 trial failed to show a statistically significant benefit in steroid-refractory acute GVHD.

Could itacitinib still be licensed to another company?

Yes, but the commercial case is weak without new clinical data. A license would likely require contingent economics tied to proof-of-concept and regulatory milestones.

Is itacitinib a competitor to Jakafi?

Itacitinib was mechanistically differentiated as a selective JAK1 inhibitor, while Jakafi inhibits JAK1 and JAK2. In commercial terms, Jakafi has the stronger position because it is approved and marketed for GVHD.

Can a generic version of itacitinib launch?

There is no conventional generic launch pathway today because itacitinib has no FDA-approved reference-listed drug. A future developer would need to address patent rights and pursue an appropriate full-application regulatory route.

References

  1. Incyte Corporation. (2021). Incyte announces topline results from Phase 3 GRAVITAS-301 trial of itacitinib in acute graft-versus-host disease. Incyte investor and corporate communications.

  2. U.S. Food and Drug Administration. (2021). FDA approves ruxolitinib for steroid-refractory acute graft-versus-host disease. FDA.

  3. U.S. Food and Drug Administration. (2021). FDA approves belumosudil for adult patients with chronic graft-versus-host disease. FDA.

  4. U.S. Food and Drug Administration. (2024). Drugs@FDA and Orange Book resources. FDA.

  5. ClinicalTrials.gov. (2021). A study of itacitinib in participants with acute graft-versus-host disease: GRAVITAS-301. U.S. National Library of Medicine.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.